A Two-arm, Open-label, Single-sequence, Multiple-dose, Cross-over Study to Evaluate the Pharmacokinetic Interaction and the Safety of UIC202502 and UIC202505 in Healthy Adult Volunteers

NCT ID: NCT07162441

Last Updated: 2025-09-09

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-08-12
• Study Completion Date: 2026-03-01

Brief Summary

This study is open-label, multiple-dose, two-intervention group, single-sequence, crossover design to compare the safety and pharmacokinetics of UIC202502 and UIC202505 when administered alone or in combination.

Conditions

Dyslipidemia

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm A

Group Type: EXPERIMENTAL

treatment A

Intervention Type: DRUG

UIC202502 1 Tab/day for 7 days

treatment C

Intervention Type: DRUG

UIC202502+UIC202505 2 Tab/day for 7 days

Arm B

Group Type: EXPERIMENTAL

treatment B

Intervention Type: DRUG

UIC202505 1 Tab/day for 7 days

treatment C

Intervention Type: DRUG

UIC202502+UIC202505 2 Tab/day for 7 days

Interventions

treatment A

UIC202502 1 Tab/day for 7 days

Intervention Type: DRUG

treatment B

UIC202505 1 Tab/day for 7 days

Intervention Type: DRUG

treatment C

UIC202502+UIC202505 2 Tab/day for 7 days

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Subjects aged 19 years or older at the time of screening.
• Subjects with a body weight greater than 50 kg (≥45 kg for females) and a body mass index (BMI) between 18.0 and 30.0 kg/m² at screening.

(BMI (kg/m²) = weight (kg) / height (m)²)

• Subjects with no clinically significant congenital or chronic diseases, pathological symptoms or findings at screening.
• Subjects determined by the principal investigator to be suitable for diagnostic procedures and electrocardiogram assessments
• Subjects who agree to use an effective method of contraception (excluding hormonal agents) recognized as appropriate in clinical trials from the first administration of the investigational drug until 14 days after the last administration, together with their spouse or partner.
• Subjects who have provided written informed consent after receiving a full explanation and demonstrating an understanding of the purpose, procedures, and characteristics of this clinical trial and the investigational drug.

Exclusion Criteria

• Subjects with clinically significant diseases or a history of conditions involving the digestive, cardiovascular, endocrine, respiratory, hematologic/oncologic infectious, renal/genitourinary, psychiatric/neurologic, musculoskeletal, immune, otorhinolaryngologic, dermatologic, or ophthalmologic systems.
• Subjects with a history of gastrointestinal surgery (excluding simple appendectomy or hernia repair) or gastrointestinal disease that may affect drug absorption.
• Subjects who have taken drugs that induce or inhibit drug-metabolizing enzymes (e.g., barbiturates) within 1 month before the first dose, or drugs that may interfere with this clinical trial within 10 days before the first dose
• Subjects who have participated in another clinical trial or bioequivalence study and received an investigational drug within 6 months before the first administration.
• Subjects who have donated whole blood or blood components within 2 weeks, or received a blood transfusion within 4 weeks before the first administration.
• Subjects who meet any of the following criteria within 1 month before the first dose:

• Average alcohol consumption exceeding 21 drinks/week for men
• Average alcohol consumption exceeding 14 drinks/week for women

(1 drink = 50 mL soju, 30 mL liquor, or 250 mL beer)

• Smoking more than 20 cigarettes/day on average
• Female subjects who are pregnant, suspected of being pregnant, or lactating

• Minimum Eligible Age: 19 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Korea United Pharm. Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

H plus Yangji Hospital

Seoul, Gwanak-gu, South Korea

Site Status: RECRUITING

Countries

South Korea

Facility Contacts

Seung hyun Kang

Role: primary

1877-8875

Other Identifiers

KUP-UI113-101

Identifier Type: -

Identifier Source: org_study_id